AstraZeneca 與 Bristol Myers Squibb 將合併？分析其利弊 (NYSE:AZN)
· seekingalpha.com
傳聞 AstraZeneca 與 Bristol Myers Squibb 將進行巨額合併：專利懸崖、腫瘤學協同效應與關鍵風險——立即獲取股票投資建議。
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...